is glp-1 for weight loss Drugs from the Gray Market Is GLP-1 the Same as

Results The first cohort included 36082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234028 DPP-4 inhibitor users (median follow-up 1.7 years)

Nutrient Gaps

Adverse reactions were compared between combination therapy and monotherapy (GLP-1 RAs or metformin alone), followed by stratified analyses by gender, age, and body weight

Many therapy areas had high growth in days of therapy in 2023 led by GLP-1 agonists driving obesity and diabetes. As the bar chart clearly tells us from the 3rd line on the bottom of the graph, obesity leads the top 30 therapy areas by growth from 2022

For US HCPs.

Explore the wider health benefits linked to GLP-1 weight loss medications beyond weight management alone by clicking here.